Theme: oncology--molecular mechanisms determining the efficacy of EGF receptor-specific tyrosine kinase inhibitors help to identify biomarker candidates.
Explore this paper's citation graph
Summary
Recent understandings of the molecular mechanisms that determine the efficacy of EGFR-tyrosine kinase inhibitors are summarized and recent ongoing projects validating potential biomarkers are discussed.
- Type
- article
- Published
- 2009-04-07
- Cited by
- 3
- References
- 123
- OpenAlex
- https://openalex.org/W1972880308
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:2960931
Keywords
Gefitinib, Erlotinib, Medicine, Lung cancer, Tyrosine kinase
References
- EGFR Mutation Status in Japanese Lung Cancer Patients: Genotyping Analysis Using LightCycler
- ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC).
- The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.
- Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer.
- BRAF and RAS mutations in human lung cancer and melanoma.
- Structure of the Extracellular Region of HER3 Reveals an Interdomain Tether
- The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.
- Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.
- Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor alpha.
- Cigarette smoking is strongly associated with mutation of the K‐ras gene in patients with primary adenocarcinoma of the lung
- Epidermal growth factor receptor mutations in lung cancer
- EGFR and HER2 Gene Copy Number and Response to First-Line Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer (NSCLC)
- Erlotinib in lung cancer - molecular and clinical predictors of outcome.
- ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors
- Rapid polymerase chain reaction-based detection of epidermal growth factor receptor gene mutations in lung adenocarcinomas.
- EGFR exon 20 insertion mutation in Japanese lung cancer.
- Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib
- Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
- Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
- Somatic mutations of the ERBB4 kinase domain in human cancers
Cited by
Related papers
- Comparison of the therapeutic outcome between gefitinib and erlotinib in female patients with non-small-cell lung cancer
- Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.
- Successful treatment of non-small cell lung cancer with gefitinib after severe erlotinib-related hepatotoxicity.
- Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment
- Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
- [Gefitinib versus Erlotinib as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer].
- Comparison of the efficacy of gefitinib and erlotinib as a second line treatment for advanced non-small cell lung cancer
- Long-term survival of non-small-cell lung cancer patients with EGFR inhibitor treatment.
- Sequential responses of adenocarcinoma of the lung to erlotinib after gefitinib in never smoker Korean woman.
- Successful treatment of non-small cell lung cancer with gefitinib after erlotinib-induced severe eyelid erosion: Two case reports.